Hemodiafiltration With Endogenous Reinfusion on Uremic Toxins Clearance of Maintenance Hemodialysis Patients

Inclusion Criteria: * 18-75 years old, regardless of gender. * MHD for at least 3 months, and blood purification treatment for 3 times per week. * The vascular access is autogenous arteriovenous fistula or artificial blood vessels，with a blood flow ≥200mL/min. * spKt/V≥1.2. * Patients who signed the informed consent form (ICF) voluntarily. Exclusion Criteria: * Patients who have participated in other interventional clinical trials within a month. * Pregnant or lactating women. * Patients of NYHA class IV or occurred acute coronary syndrome or myocardial infarction in 3 months before the start of the study. * Patients with active hemorrhage in 2 weeks (e.g., cerebral hemorrhage, gastrointestinal hemorrhage, fundus hemorrhage, etc.). * Patients with unstable blood pressure (pre-dialysis systolic blood pressure ≥180 or ≤90mmHg, pre-dialysis diastolic blood pressure ≥100 or ≤60mmHg), severe anemia (hemoglobin ≤60g/L), and high risk of blood coagulation (e.g., albumin ≤25g/L or hemoglobin ≥140g/L). * Patients with severe infection (the level of hypersensitive C-reactive protein(hsCRP) ≥ 10×upper limit of normal). * Patients with a history of drug addiction or severe mental disorders. * Other conditions in which the investigators reject patients to participate in this study.